Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration
Tuberculosis (TBC) is characterized by a complex immune response which parallels the clinical course of the disease. In this respect, acquired resistance, delayed hypersensitivity reaction and anergy are the main types of immune reactivity to mycobacterial antigens. In view of the presence of nonspe...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1993-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/S0962935193000699 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558864979984384 |
|---|---|
| author | Emilio Jirillo Maria Altamura Carlo Marcuccio Cosimo Tortorella Claudio De Simone Salvatore Antonaci |
| author_facet | Emilio Jirillo Maria Altamura Carlo Marcuccio Cosimo Tortorella Claudio De Simone Salvatore Antonaci |
| author_sort | Emilio Jirillo |
| collection | DOAJ |
| description | Tuberculosis (TBC) is characterized by a complex immune response which parallels the clinical course of the disease. In this respect, acquired resistance, delayed hypersensitivity reaction and anergy are the main types of immune reactivity to mycobacterial antigens. In view of the presence of nonspecific and specific immune deficits in TBC patients, a clinical trial was carried out in a group of 20 individuals with active pulmonary TBC by oral administration of acetyl-L-carnitine (ALC). This drug, which has been shown to possess immunomodulating activities, was able to upregulate the T-dependent antibacterial activity in TBC patients after 30 days' treatment, while the same activity decreased in patients receiving placebo only. On the other hand, ALC did not modify serum levels of tumour necrosis factor-α, in the same individuals. This cytokine plays a detrimental rather than beneficial role in TBC pathogenesis. In the light of these data, ALC seems to be a powerful immunomodulator in the course of Mycobacterium tuberculosis infection and other mycobacteriosis. |
| format | Article |
| id | doaj-art-6a49552207374d529dd2df64c1aaad17 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 1993-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-6a49552207374d529dd2df64c1aaad172025-02-03T01:31:26ZengWileyMediators of Inflammation0962-93511466-18611993-01-0127S17S2010.1155/S0962935193000699Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administrationEmilio Jirillo0Maria Altamura1Carlo Marcuccio2Cosimo Tortorella3Claudio De Simone4Salvatore Antonaci5Immunologia, Medical School, University of Bari, Bari, ItalyImmunologia, Medical School, University of Bari, Bari, ItalyImmunologia, Medical School, University of Bari, Bari, ItalyMedicina Interna, Medical School, University of Bari, Bari, ItalyMalattie Infettive, Medical School, University of L'Aquila degli Abruzzi, L'Aquila, ItalyMedicina Interna, Medical School, University of Bari, Bari, ItalyTuberculosis (TBC) is characterized by a complex immune response which parallels the clinical course of the disease. In this respect, acquired resistance, delayed hypersensitivity reaction and anergy are the main types of immune reactivity to mycobacterial antigens. In view of the presence of nonspecific and specific immune deficits in TBC patients, a clinical trial was carried out in a group of 20 individuals with active pulmonary TBC by oral administration of acetyl-L-carnitine (ALC). This drug, which has been shown to possess immunomodulating activities, was able to upregulate the T-dependent antibacterial activity in TBC patients after 30 days' treatment, while the same activity decreased in patients receiving placebo only. On the other hand, ALC did not modify serum levels of tumour necrosis factor-α, in the same individuals. This cytokine plays a detrimental rather than beneficial role in TBC pathogenesis. In the light of these data, ALC seems to be a powerful immunomodulator in the course of Mycobacterium tuberculosis infection and other mycobacteriosis.http://dx.doi.org/10.1155/S0962935193000699 |
| spellingShingle | Emilio Jirillo Maria Altamura Carlo Marcuccio Cosimo Tortorella Claudio De Simone Salvatore Antonaci Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration Mediators of Inflammation |
| title | Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration |
| title_full | Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration |
| title_fullStr | Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration |
| title_full_unstemmed | Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration |
| title_short | Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration |
| title_sort | immunological responses in patients with tuberculosis and in vivo effects of acetyl l carnitine oral administration |
| url | http://dx.doi.org/10.1155/S0962935193000699 |
| work_keys_str_mv | AT emiliojirillo immunologicalresponsesinpatientswithtuberculosisandinvivoeffectsofacetyllcarnitineoraladministration AT mariaaltamura immunologicalresponsesinpatientswithtuberculosisandinvivoeffectsofacetyllcarnitineoraladministration AT carlomarcuccio immunologicalresponsesinpatientswithtuberculosisandinvivoeffectsofacetyllcarnitineoraladministration AT cosimotortorella immunologicalresponsesinpatientswithtuberculosisandinvivoeffectsofacetyllcarnitineoraladministration AT claudiodesimone immunologicalresponsesinpatientswithtuberculosisandinvivoeffectsofacetyllcarnitineoraladministration AT salvatoreantonaci immunologicalresponsesinpatientswithtuberculosisandinvivoeffectsofacetyllcarnitineoraladministration |